custom image

Vaccinology in the Age of Pandemics:
Strategies Against COVID-19 & Other Global Threats

June 15–16, 2020 | 11:00AM–3:30PM ET | 3:00–7:30PM UTC | 5:00–9:30PM CEST*
*Program is subject to change



custom image


Journal of Experimental Medicine (JEM)

 

Journal of Experimental Medicine (JEM) publishes papers providing novel conceptual insight into immunology, neuroscience, cancer biology, vascular biology, microbial pathogenesis, and stem cell biology. All editorial decisions are made by active scientists in conjunction with professional editors. JEM was established in 1896. Carl Nathan and Michel Nussenzweig serve as JEM Editorial Board Co-Chairs. Dr. Nathan is the R.A. Rees Pritchett Professor and Chairman of the Department of Microbiology and Immunology at Weill Cornell Medicine. Dr. Nussenzweig is the Zanvil A. Cohn and Ralph M. Steinman Professor at The Rockefeller University, Investigator at Howard Hughes Medical Institute, and Senior Physician. Teodoro Pulvirenti serves as JEM Executive Editor. Learn more about JEM editors.

Editors attending this meeting

Gaia Trincucci, Scientific Editor

Gaia received her PhD in Cell Biology from the University of Basel, Switzerland, studying the role of Type III interferons in chronic hepatitis C. She pursued her postdoctoral work with Abraham Brass and Kate Fitzgerald at University of Massachusetts Medical School, focusing on uncovering novel host factors in viral replication. She joined the Journal of Experimental Medicine as a Scientific Editor in 2018. Gaia is in charge of JEM Viewpoints.

Email Gaia to discuss your research: gtrincucci@rockefeller.edu

Teodoro Pulvirenti, Executive Editor, JEM; Director of Editorial Development, RUP

Teodoro (Teo) received his PhD from the Mario Negri Sud Institute in Italy. He then carried out his postdoctoral work in the lab of Alan Hall at Memorial Sloan Kettering Cancer Center, studying the role of Wnt signaling in cancer stem cells, and continued this line of research in the lab of Eric Holland at the same institution. Teo started his editorial career at the Journal of Experimental Medicine (JEM) in 2013. He then joined Nature Cell Biology as Senior Editor, and returned to JEM as Executive Editor in 2016. He is also the Director of Editorial Development for Rockefeller University Press.

JEM Articles related to COVID-19 / SARS-CoV-2

Viewpoint | March 30, 2020
Forty years with coronaviruses
Susan R. Weiss

Editorial | March 31, 2020
We are here for you and ready to hear from you
Carl F. Nathan, Michel C. Nussenzweig, Teodoro Pulvirenti

Viewpoint | April 14, 2020
COVID-19 and emerging viral infections: The case for interferon lambda
Ludmila Prokunina-Olsson, Noémie Alphonse, Ruth E. Dickenson, Joan E. Durbin, Jeffrey S. Glenn, Rune Hartmann, Sergei V. Kotenko, Helen M. Lazear, Thomas R. O'Brien, Charlotte Odendall, Olusegun O. Onabajo, Helen Piontkivska, Deanna M. Santer, Nancy C. Reich, Andreas Wack, Ivan Zanoni

Perspective | April 16, 2020
Targeting potential drivers of COVID-19: Neutrophil extracellular traps
Betsy J. Barnes, Jose M. Adrover, Amelia Baxter-Stoltzfus, Alain Borczuk, Jonathan Cools-Lartigue, James M. Crawford, Juliane Daßler-Plenker, Philippe Guerci, Caroline Huynh, Jason S. Knight, Massimo Loda, Mark R. Looney, Florencia McAllister, Roni Rayes, Stephane Renaud, Simon Rousseau, Steven Salvatore, Robert E. Schwartz, Jonathan D. Spicer, Christian C. Yost, Andrew Weber, Yu Zuo, Mikala Egeblad

Perspective | April 30, 2020
The many faces of the anti-COVID immune response
Santosha A. Vardhana and Jedd D. Wolchok

Why submit your research to JEM?

At JEM, all editorial decisions on research manuscripts are made through collaborative consultation between professional scientific editors and the academic editorial board. JEM implements editorial policies with highly productive investigators in mind.

Format Neutral: You may submit your papers in ANY format.

Transfer Policy: We welcome submissions that include reviewer comments from another journal. You may also request manuscript transfer between Rockefeller University Press journals, and we can confidentially send reviewer reports and identities to another journal beyond RUP.

Fair and Fast: We limit rounds of revision, and we strive to provide clear, detailed decisions that illustrate what is expected in the revisions. Articles appear online one to two days after author proofs are returned.

Open Access Options: Our options include Immediate Open Access (CC-BY) and open access six months after publication (CC-BY-NC-SA).

JEM Highlights:

  • 92% of invited revisions are accepted
  • initial decision in 6 days
  • time in peer review 38 days

Learn more about submitting your research to JEM

 
custom image


EMBO Molecular Medicine


EMBO Molecular Medicine is the top open access journal in the field of experimental medicine dedicated to science at the interface between translational and clinical research and basic life sciences. The journal welcomes original studies performed in cells and/or animals provided that they demonstrate evident human disease relevance. Submission of first-in-human studies and analyses of patient samples are also encouraged.

The journal is one of four EMBO Press journals run by in-house professional scientific editors. EMBO Molecular Medicine is supported by academic Chief Editor, Prof. Philippe Sansonetti, nine academic Senior Editors and a broad and diverse advisory editorial board. Click here to learn more about the editors and the topics covered in the journal.


Editors attending this meeting


Céline Carret, Senior Scientific Editor

Céline Carret completed her PhD at the University of Montpellier, France, characterising host immunodominant antigens to fight babesiosis, a parasitic disease caused by a unicellular Apicomplexan parasite closely related to the malaria agent Plasmodium. She further developed her post-doctoral career on malaria working at the Wellcome Trust Sanger Institute in Cambridge, UK and Instituto de Medicina Molecular in Lisbon, Portugal. Céline joined EMBO Molecular Medicine as a Scientific Editor in March 2011.

Email Céline to discuss your research: c.carret@embomolmed.org


Zeljko Durdevic, Scientific Editor

Zeljko received his PhD from the University of Heidelberg / German Cancer Research Center, where he investigated the function of DNA methyltransferase 2 uncovering that this enzyme plays important roles in innate immunity, stress responses and genome stability. He carried out his postdoctoral research in the laboratory of Anne Ephrussi at EMBL, where he focused on the role of the RNA helicase Vasa in germ cell lineage homeostasis and genome stability. Zeljko joined EMBO Molecular Medicine as a Scientific Editor in January 2020.

Email Zeljko to discuss your research: z.durdevic@embomolmed.org


Covid-19 research published in EMBO Molecular Medicine


Interview | 24 April 2020

10 Questions and 4 experts on Corona

Interview with Akiko Iwasaki, Gérard Krause, Samuel Alizon, and Rino Rappuoli

Celine K Carret


Commentary | 28 April 2020

Why does Japan have so few cases of COVID‐19?

Akiko Iwasaki, Nathan D Grubaugh


Editorial | 4 May 2020

COVID‐19, chronicle of an expected pandemic

Philippe J Sansonetti


Commentary | 5 May 2020

The prospects for the SARS‐CoV‐2 pandemic in Africa

Virginia Quaresima, Matteo M Naldini, Daniela M Cirillo


Article | 19 May 2020

The role of interleukin‐6 in monitoring severe case of coronavirus disease 2019

Tao Liu, Jieying Zhang, Yuhui Yang, Hong Ma, Zhenyu Li, Jiaoyue Zhang, Ji Cheng, Xiaoyun Zhang, Yanxia Zhao, Zihan Xia, Liling Zhang, Gang Wu, Jianhua Yi


Commentary | 25 May 2020

COVID‐19: lambda interferon against viral load and hyperinflammation

Evangelos Andreakos, Sotirios Tsiodras


Commentary | 26 May 2020

Is BCG vaccination causally related to reduced COVID‐19 mortality?

Masayuki Miyasaka


Opinion | 26 May 2020

SARS‐CoV‐2, bacterial co‐infections, and AMR: the deadly trio in COVID‐19?

Jose A. Bengoechea, Connor G.G. Bamford


Correspondence | 27 May 2020

‘All In’: a pragmatic framework for COVID‐19 testing and action on a global scale

Syril D Pettit, Keith R Jerome, David Rouquié, Bernard Mari, Pascal Barbry, Yasunari Kanda, Mineo Matsumoto, Susan Hester, Leah Wehmas, Jason W Botten, Emily A Bruce


Learn more about submitting your research to EMBO Molecular Medicine

 
custom image


Journal of Clinical Investigation (JCI)


The Journal of Clinical Investigation (JCI), established in 1924 and published by the American Society for Clinical Investigation, is a peer-reviewed journal publishing discoveries in basic and clinical biomedical science that will advance the practice of medicine. Research of interest spans all biomedical specialties, including infectious diseases, immunology, autoimmunity, gastroenterology, metabolism, nephrology, neuroscience, oncology, cardiology, and others. The JCI also publishes reviews, commentaries, viewpoints, editorials, and feature items. The editorial board, based at Johns Hopkins University, is led by editor-in-chief Rexford S. Ahima and supported by Executive Editor Sarah Jackson and Science Editors Corrine Williams, Elyse Dankoski, and Lisa Conti. Contact the editors at editors@the-jci.org.

All research published in the JCI is freely available immediately upon publication on the journal’s website and is also deposited in PubMed Central. The journal is supported by publication fees and meets mandates from funding agencies (including Wellcome) for open access publication. Learn more about submitting your paper to the JCI.

Recently published COVID-19 articles in the JCI:

Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent

Alessio Mazzoni, … , Francesco Annunziato, Lorenzo Cosmi

Clinical Medicine, Published May 28, 2020

New York City COVID-19 resident physician exposure during exponential phase of pandemic

Mark P. Breazzano, … , Alice Chen-Plotkin, Royce W.S. Chen

Clinical Medicine, Published May 28, 2020

COVID-19, microangiopathy, hemostatic activation, and complement

Wen-Chao Song, Garret A. FitzGerald

Viewpoint, Published May 27, 2020

Clinical trials for COVID-19 should include sex as a variable

Evelyne Bischof, … , Jeannette Wolfe, Sabra L. Klein

Viewpoint, Published May 11, 2020

Prototype pathogen approach for pandemic preparedness: world on fire

Barney S. Graham, Kizzmekia S. Corbett

Viewpoint, Published April 30, 2020

Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists

Maximilian F. Konig, … , Shibin Zhou, Chetan Bettegowda

Viewpoint, Published April 30, 2020

Panic prescribing has become omnipresent during the COVID-19 pandemic

Arthur L. Caplan, Ross Upshur

Viewpoint, Published April 24, 2020

Deployment of convalescent plasma for the prevention and treatment of COVID-19

Evan M. Bloch, … , Jeffrey A. Bailey, Aaron A.R. Tobian

Review, Published April 7, 2020

Kidney diseases in the time of COVID-19: major challenges to patient care

Hamid Rabb

Viewpoint, Published April 6, 2020

The COVID-19 pandemic and research shutdown: staying safe and productive

M. Bishr Omary, … , Reynold A. Panettieri Jr., Kathleen W. Scotto

Viewpoint, Published April 3, 2020

COVID-19 threatens health systems in sub-Saharan Africa: the eye of the crocodile

Elijah Paintsil

Viewpoint, Published March 30, 2020

SARS-CoV-2: a storm is raging

Savannah F. Pedersen, Ya-Chi Ho

Commentary, Published March 27, 2020

Clinical and immunological features of severe and moderate coronavirus disease 2019

Guang Chen, … , Jianping Zhao, Qin Ning

Clinical Medicine, Published March 27, 2020

Changing the editorial process at JCI and JCI Insight in response to the COVID-19 pandemic

Rexford S. Ahima, … , Donna M. Martin, Pavan Reddy

Editorial, Published March 23, 2020

The convalescent sera option for containing COVID-19

Arturo Casadevall, Liise-anne Pirofski

Viewpoint, First published March 13, 2020

The editors of JCI and JCI Insight have revised the editorial process to address the impact of the COVID-19 pandemic on the global research community. Highlights:

  • The editors may choose to be more lenient regarding revision requests if the requested experiments do not fundamentally change the conclusions
  • The editors may overrule requests from reviewers that the editorial board deems to be beyond the scope of reasonable revision
  • If additional studies are required, the editors want to ensure that authors have adequate time to perform the work
 
custom image


Frontiers


Frontiers is an award-winning Open Science platform and leading Open Access scholarly publisher. Our mission is to make research results openly available to the world, thereby accelerating scientific and technological innovation, societal progress and economic growth. Covering more than 600 academic disciplines, our 80+ journals are led and peer-reviewed by editorial boards of over 100,000 top researchers.

Recognizing the exceptional nature of the COVID-19 pandemic, Frontiers has established a priority peer-review process and waived Article Processing Charges (APCs) until 31 July 2020 for manuscripts submitted in response to the pandemic. We particularly encourage researchers to launch and contribute to Research Topics on coronavirus: highly visible article collections showcasing emerging and important areas of COVID-19 research across multiple disciplines.


Editors attending this meeting


Denise Doolan, Specialty Chief Editor, Frontiers in Immunology - Vaccines and Molecular Therapeutics

Professor Denise Doolan is Deputy Director of the Australian Institute of Tropical Health & Medicine (AITHM) at James Cook University, Australia. A molecular immunologist, her research focuses on developing novel immunotherapeutics and immunodiagnostics for complex pathogens that cause chronic diseases, using malaria as a model. Much of her career has focused on malaria immunology and vaccine development. Most recently, she is moving into the area that intersects infectious and chronic disease.

Alessandra Fornarelli, Journal Manager, Frontiers in Immunology

Alessandra Fornarelli graduated from the University of Piemonte Orientale in Novara, Italy, and completed a doctoral degree at the University of Bonn, Germany, working at the German Center for Neurodegenerative diseases (DZNE) in the laboratory led by Professor Pierluigi Nicotera. She joined Frontiers in 2016, working on several journals before becoming journal manager for Frontiers in Immunology in January 2018.

Email Alessandra to discuss your research: alessandra.fornarelli@frontiersin.org


Frontiers Research Topics related to COVID-19 & vaccines


COVID-19: Pathophysiology, epidemiology, clinical management and public health response
163 articles | Led by Denise Doolan & 12 other leading researchers

Interdisciplinary research addressing knowledge gaps and generating evidence for the improved management and control of COVID-19, with scientific contributions from all areas of virology, immunology, clinical microbiology, epidemiology, therapeutics, communications as well as infection prevention and public health risk assessment and management studies.

COVID-19: Molecular mechanisms, translational approaches and therapeutics
Open for submissions | Led by José A G Agúndez & 20 leading researchers

Aims to highlight advances in the clinical diagnosis of COVID-19, molecular mechanisms and pathology of the disease in different populations, therapeutic target identification, and drug and vaccine development towards patient treatment and prevention of disease.

Control of vaccine-preventable diseases across the whole of life
Open for submissions | Led by Chandini Raina MacIntyre & Daniel A Salmon

Seeks manuscripts on pediatric and adult vaccine-preventable diseases, as well as vaccines for emerging and re-emerging infectious diseases including COVID-19. Methodologies can include epidemiology, public health, clinical trials, mathematical modelling, health economic modelling, and social or behavioral research.

DNA vaccines
Open for submissions | Led by Ada Maria De Barcelos Alves, Silvia Beatriz Boscardin & Annie Elong Ngono

Welcomes original research, reviews, opinion and perspective articles on DNA vaccines for prevention against infection by pathogens, treatment of different diseases, understanding the mechanisms involved in the activation of immune responses elicited by these vaccines, improvement in vivo transfection, and antigen expression.

» See all COVID-19-related Research Topics
»
See all COVID-19-related articles
»
Coronavirus Knowledge Hub: the latest science & resources


Why launch a Frontiers Research Topic?


Frontiers’ Research Topics are peer-reviewed article collections around cutting-edge research themes. Defined, managed and led by renowned researchers, they unite the world’s leading experts around the hottest topics, stimulating collaboration and accelerating science. Managed and disseminated on Frontiers’ Open Science platform, these collections are free to access and highly visible, increasing readership and citations for your research.


Frontiers highlights


  • Gold open-access publisher
  • 5th most-cited of world's 20 largest publishers
  • Rigorous, constructive, efficient and transparent peer review
  • Average time from submission to final decision: 90 days